; (ii) the location of the fatal overdose, including whether the overdose was on a military base; and (iii) a list of the substances involved in the fatal overdose. (B) Of the covered members identified in subparagraph (A)— (i) the number of covered members who received mental health or substance use disorder services prior to a fatal or nonfatal overdose, including a description of whether such services were received from a private sector provider; (ii) the number of covered members with comorbid mental health diagnoses; (iii) the number of covered members who had been prescribed opioids, benzodiazepines, or stimulants; (iv) the number of covered members who had been categorized as high-risk and prescribed or provided naloxone prior to a fatal or nonfatal overdose; (v) the number of covered members who had a positive drug test prior to the fatal overdose, including any substance identified in such test; (vi) the number of covered members referred to, including by self-referral, or engaged in medical treatment, including medication treatment for opioid use disorder; (vii) with respect to each covered member identified in clause (vi), whether the covered member was referred after a positive drug test and the source of such referral